Pure red cell aplasia (PRCA) is a well-known marrow failure which may be acquired or constitutional/congenital, as the Diamond-Blackfan syndrome. Acquired PRCA may show as a primary hematological disorder or secondary to an associated disease, infection or drug. PRCA rarely complicates chronic lymphocytic leukemia (CLL), may occur anytime in the course of the disease and, in this context, it is a minority of total PRCA. Anemia due to PRCA in CLL patients must be carefully evaluated and differentiated from other causes (autoimmune hemolytic anemia, neoplastic lymphocyte infiltration of bone marrow, chemotherapy) that require a different therapeutic approach. PRCA is thought to be an immunologically mediated disorder, but there is no uniformity in the setting of the management. Immunosuppressive therapy is frequently given, such as steroids and cyclosporin-A. Recently, anecdotal cases have been published on the effectiveness of monoclonal antibodies rituximab and alemtuzumab.
DessyprisEN. Pure red cell aplasia. In: Hematology Basic Principles and Practice. HoffmanRBenzEJJrShattilSJFurieBCohenHJSilbersteinLEMcGlaveP, eds. Philadelphia: Elsevier Churchill Livingstone; 2005; pp. 429–439.
ChikkappaGZarrabiMHTsanMF. Pure red cell aplasia in patients with chronic lymphocytic leukemia. Medicine1986; 65:339–51.
4.
DiehlLFKetchumLH. Autoimmune diseases and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol1998; 25:80–97.
5.
HamblinTJ. Autoimmune disease and its management in chronic lymphocytic leukemia. In: ChesonBD, ed. Chronic lymphoid leukemias. New York: Marcel Dekker; 2000; pp. 435–58.
YoungNSAbkowitzJLLuzzattoL. New insights into the pathophysiology of acquired cytopenias. Am Soc Hematol Educ Program2000:18–38.
8.
KrantzSBKaoV. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA1967; 58:493–500.
9.
KrantzSBKaoV. Studies on red cell aplasia. II. Report of a second patient with an antibody to erythroblast nuclei and a remission after immunosuppressive therapy. Blood1969; 34:1–13.
10.
KrantzSBMooreWHZaentzSD. Studies on red cell aplasia. V. Presence of erythroblast cytotoxicity in G-globulin fraction of plasma. J Clin Invest1973; 52: 324–36.
11.
ZaentzSDKrantzSB. Studies on pure red cell aplasia. VI. Development of two-stage erythroblast cytotoxicity method and role of complement. J Lab Clin Med1973; 82:31–43.
12.
CharlesRJSaboKMKiddPGAbkowitzJL. The pathophysiology of pure red cell aplasia: Implications for therapy. Blood1996; 87:4831–8.
13.
KeelSAbkowitzJL. Pure red cell aplasia and Diamond-Blackfan anemia. In: YoungNSGersonSLHighKA, Eds. Clinical Hematology. Mosby Elsevier, Philadelphia, USA, 2006; pp. 169–180.
14.
HoffmanRKopelSHsuSDDainiakNZanjaniED. T-cell chronic lymphocytic leukemia: Presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood1978; 52:255–60.
15.
ManganKFChikkappaGScharfmanWBDesforgesJF. Evidence for reduced erythroid burst (BFU-E) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol1981; 9:489–98.
16.
ManganKFChikkappaGBielerLZScharfhanWBParkinsonDR. Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood1982; 59:990–6.
17.
ManganKFChikkappaGFarleyPC. T gamma (Tγ) cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest1982; 70:1148–56.
18.
ManganKFD'AlessandroL. Hypoplastic anemia in B cell chronic lymphocytic leukemia: Evolution of T cell mediated suppression of erythropoiesis in early-stage and late-stage disease. Blood1985; 66:533–41.
19.
AbkowitzJLKadinMEPowellJSAdamsonJW. Pure red cell aplasia: Lymphocyte inhibition of erythropoiesis. Br J Haematol1986; 63:59–67.
20.
ManganKFVolkinRWinkelsteinA. Autoreactive erythroid progenitor-T suppressor cells in the pure red cell aplasia associated with thymoma and panh ypogammaglobulinemia. Am J Hematol1986; 23:167–73.
21.
HakardLPBrandtJLuLJansenJHoffmanR. Chronic T cell lymphoproliferative disorder and pure red cell aplasia. Am J Med1987; 83:1069–74.
22.
NagasawaTAbeTNakagawaT. Pure red cell aplasia and hypogammaglobulinemia associated with Tr-cell chronic lymphocytic leukemia. Blood1981; 57:1025–31.
23.
LacyMQKurtinPJTefferiA. Pure red cell aplasia: Association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood1996; 87:3000–6.
24.
HandgretingerRGeiselhartAMorisAGrauRTeuffelOBethgeWKanzLFischP. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med1999; 340:278–84.
25.
GreerJPKinneyMCLoughranTPJr. T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Progr2001; 259–81.
26.
VashiPPatelBMussonPFahrnerJRosenbaumR. Corticosteroid-responsive pure red cell aplasia in chronic lymphocytic leukemia. Am J Hematol1987; 26:279–84.
27.
SawadaKFujishimaNHirokawaM. Acquired pure red cell aplasia: Updated review of treatment. Br J Haematol2008; 142:505–14.
28.
ChikkappaGPasqualeDPhillipsPGManganKFTsanMF. Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia. Am J Hematol1987; 26:179–89.
29.
CesanaCCarlo-StellaCMangoniLAlmiciCGiachettiRZappaMRizzoliV. Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia. Leukemia1996; 10:1400–1.
30.
TuraSFinelliCBandiniGCavoMGobbiM. Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia. Nouv Rev Fr Hematol1988; 30:479–81.
31.
FinelliCBandiniGRicciPGiudiceVVianelliNRabbiCRaspadoriDTuraS. Cyclosporin A in idiopathic and CLL-associated pure red cell aplasia. Haematologica1987; 72:537–40.
32.
ChristenRMorantRFehrJ. Cyclosporin A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukaemia. Eur J Haematol1989; 42:303–7.
33.
YamadaOYun-HuaWMotojiTMizoguchiH. Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukemia: Successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity. Br J Haematol1998; 101:335–7.
34.
GoticMBasaraNRolovicZBoskovicDAntunovicPMarisavljevicDBrkicS. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic leukemia with cyclosporine A: Correlation between clinical and in vitro effects. Nouv Rev Fr Hematologie1994; 36:307–9.
35.
SivakumaranMBhavnaniM. Cyclosporin therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia (letter; comment). Am J Hematol1994; 45:192.
36.
ChikkappaGPasqualeDZarrabiMHWeilerRJDivakaraMTsanMF. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J hematol1992; 41:5–12.
37.
CortesJO'BrienSLoscertalesJKantarjianHGilesFThomasDKollerCKeatingM. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer2001; 92:2016–22.
38.
SingalRWinfieldDAGreavesM. Bone marrow aplasia in B cell chronic lymphocytic leukaemia: Successful treatment with antithymocyte globulin. J Clin Pathol1991; 44:954–6.
39.
RadosevichCAGordonLIWeilSCMarderRJRosenST. Complete resolution of pure red cell aplasia in a patient with chronic lymphocytic leukemia following antithymocyte globulin therapy. JAMA1988; 259:723–5.
40.
GhazalH. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood2002; 99:1092–4.
41.
BattleMRiberaJ-MOriolAPensaEMillaFFeliuE. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia. Br J Haematol2002; 118:1190–200.
42.
RuXLiebmanHA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J haematol2003; 123:278–81.
43.
PantelidouDTsatalasCMargaritisDKaloutsiVSpanoudakisEBopurikasG. Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukaemia-associated pure red cell aplasia. Hematol J2004; 5:546–7.
44.
NarraKBorghaeiHAl-SaleemTHoglundMSmithMR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. Leuk Res2006; 30:109–14.
45.
D'ArenaGVigliottiMLDell'OlioM. Rituximab to treat chronic lymphoproliferative disorders-associated pure red cell aplasia. Eur J Haematol2009; 82:235–9.
46.
ScrivenerSGoddardRVKaminskiERPrenticeAG. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. Leuk Lymphoma2003; 44:383–9.
47.
HamblinTJOrchardJAMyintHOscierDG. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia (letter). J Clin Oncol1998; 16:3209–10.
48.
StasiRDel PoetaGStipaEEvangelistaMLTrawinskaMCooperNAmadoriS. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood2007; 110:2924–30.
49.
RodonPBretonPCouroubleG. Treatment of pure red cell aplasia and autoimmune haemolytic anemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol2003; 70:319–21.
50.
HaleGXiaMQTigheHPDyerMJSWaldmannH. The Campath-1H antigen (CD52). Tissue Antigen1990; 35:118–27.
